Seaport Therapeutics, Inc. (SPTX) is a pioneering biopharmaceutical firm dedicated to advancing cutting-edge immune-oncology therapies to meet critical unmet medical needs, particularly in the field of oncology. The company leverages innovative technologies and a robust research pipeline to develop targeted treatment solutions for complex diseases, with a strong focus on cancer. Supported by strategic collaborations and an experienced management team, Seaport Therapeutics is well-positioned to drive scientific advancements that enhance patient outcomes and reshape the landscape of cancer treatment and immunotherapy.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-143.75M |
| Operating Margin | 0.00% |
| Return on Equity | -28.10% |
| Return on Assets | -18.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.89 |
| Price-to-Book | 2.70 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $53.53M |
| Float | $18.43M |
| % Insiders | 35.14% |
| % Institutions | 70.99% |
Volatility is currently contracting
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress.
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance.
Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers.
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers.
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™.
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to participate in two upcoming investor conferences.
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial public offering at the top of its target range, putting the clinical-stage neuropsychiatry company on course to raise gross proceeds of $254.9 million. In London, PureTech shareholders saw the share price climb 9.56% to 139.8p.
Drug developer Seaport Therapeutics said on Thursday it had raised about $255 million in its upsized initial public offering in the United States.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SPTX and any ticker you trade — then tracks every position and per-strategy win rate.
